RBRachelle Brick

Rachelle Brick

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rachelle Brick has a total of 137 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Correction to: Breast cancer survivors’ perspectives on a clinical decision tool to support individualized exercise prescriptions and discussions

    by Oliver W. A. Wilson, Kaitlyn M. Wojcik, Eleanor M. Kerr, Ilse Rivera, Emma Tian, Jacob D. Schneider, Rachelle Brick, David Berrigan, Kosuke Tamura, Laura Q. Rogers, et al.

  • Integrating cancer rehabilitation and lifestyle medicine: a proposed partnership and case example from the RISE cancer survivorship clinic

    by Alix G. Sleight, Stephen B. Weschler, Jennifer M. Jones, Kelley C. Wood, Mackenzi Pergolotti, Courtney P. Williams, Rachelle S. Brick, Sarah Lyon, Aneesha Virani, Sandy C. Takata, et al.

    Cancer mortality is associated with modifiable health behaviors such as physical activity, alcohol intake, and diet; however, it is estimated that only 5-25% of cancer survivors adhere to health behavior recommendations after diagnosis. With the overburdened infrastructure of healthcare in the United States and the high out-of-pocket expenditures for cancer patients, it is challenging for cancer survivors to access personalized lifestyle medicine in many settings. In this Perspective, an interdisciplinary team of cancer rehabilitation and lifestyle medicine clinicians outline the potential for synergy between the two fields to illustrate the possibilities for improvement in cancer care when the two disciplines are integrated. We outline key concepts and present a case example from Re-invent, Integrate, Strengthen, Expand (RISE), an occupational therapy-based cancer survivorship clinic employing the tenets of lifestyle medicine in a major urban medical center in the United States. Cancer rehabilitation clinicians are uniquely situated to collaborate with lifestyle medicine clinicians in the assessment of lifestyle-related issues and interventions designed to mitigate these issues. The RISE cancer survivorship clinic provides a practical, real-life example of this collaboration in action. Cancer care throughout the continuum may benefit from an increase in synergistic activities between these two professional domains.

  • Open Access

    Breast cancer survivors’ perspectives on a clinical decision tool to support individualized exercise prescriptions and discussions

    by Oliver W. A. Wilson, Kaitlyn M. Wojcik, Eleanor M. Kerr, Ilse Rivera, Emma Tian, Jacob D. Schneider, Rachelle Brick, David Berrigan, Kosuke Tamura, Laura Q. Rogers, et al.

    Purpose: To examine breast cancer survivors’ perspectives on the prototype (paper-draft) of a clinical decision tool to support individualized exercise prescriptions and discussions within clinical settings. Methods: A sample of ≥90 female breast cancer survivors aged ≥35 years across the U.S. were recruited to complete an online survey that collected data on survivors’ characteristics and perspectives of a prototype of the tool. Survey items were adapted from validated pre-existing instruments and refined via cognitive interviews. Results: Ninety-eight of the 142 individuals screened were deemed eligible and completed the survey. Most breast cancer survivors agreed that a tool would be useful (84.7%) and increase confidence to discuss exercise with a healthcare provider (74.5%). Among tool uses, the highest agreement was found for education (84.1%) and encouragement to exercise (79.3%). Improving the ability to do everyday tasks (74.0%), quality-of-life (72.6%), and energy (71.4%) were rated as the top exercise benefits to include in a tool. Agreement on tool usefulness, uses, and inputs varied by survivors’ demographic, clinical, and contextual characteristics. For example, agreement that a tool would increase their confidence to discuss exercise was lower among younger survivors (<50 years, 67.7%) than older survivors (≥50 years, 78.5%). Conclusions: An evidence-based clinical decision tool offering individualized exercise information could support exercise prescriptions and discussions within clinical settings. However, a one-size-fits-all tool may not address existing disparities in exercise participation. Further research among underserved women is needed.


  • Open Access

    Healthcare provider perspectives on a clinical decision tool to support individualized exercise prescriptions and discussions for breast cancer survivors

    by Jinani Jayasekera, Oliver W. A. Wilson, Kaitlyn M. Wojcik, Eleanor M. Kerr, Rachelle Brick, David Berrigan, Jennifer Yeong-Shin Sheng, Takeo Fujii, Kathleen Thomas, Henri K. Parson, et al.

    Purpose: We evaluated healthcare providers’ current knowledge, practices, and perspectives on a novel clinical decision tool (beta-version) to facilitate individualized exercise prescriptions and discussions in clinical settings. Methods: We recruited healthcare providers who had treated or provided care to breast cancer survivors aged ≥ 35-years in the past 12 months. The participants were presented with a tool to provide individualized exercise recommendations considering women’s individual, clinical, and contextual characteristics. Validated and reliable pre-existing instruments were used to survey providers’ current knowledge, practices regarding exercise discussions, and perspectives on the beta-version (paper-draft) of the novel tool. Results: The sample consisted of complete survey responses from 177 healthcare providers including breast oncologists (27.7%), primary care physicians (10.7%), exercise specialists (19.8%), occupational/physical therapists (18.1%), advanced care providers, nurses, navigators, and social workers (23.7%). Median years of experience was 8-years (range: 5–13). Overall, 62.1% (n = 110) reported that they were knowledgeable about counseling survivors based on exercise guidelines. Among breast oncologists and primary care physicians (n = 68), only 39.7% reported that they were knowledgeable about identifying patients for exercise referals. The majority agreed that they would find the tool offering individualized information useful (n = 148, 83.6%), and would use it regularly to inform practice (82.5%). ‘Exercise Readiness’, ‘Exercise Resources at Home’, and ‘Quality-of-Life’ were the highest rated items for inclusion in the tool for exercise prescriptions. Provider perspectives were incorporated into the beta-version of the tool. Conclusion: A clinical decision tool considering individual, clinical, and contextual characteristics may support exercise prescriptions and discussions in clinical settings. Implications for cancer survivors: An evidence-based tool for exercise prescriptions may increase healthcare provider confidence to discuss, educate, encourage, and provide exercise referrals for breast cancer survivors.


  • Open Access

    Cancer and Accelerated Aging Research at the National Institutes of Health, 2013–2023: A Grant Portfolio Analysis

    by Lisa Gallicchio, Rachelle Brick, Gina Tesauro, Lindsey Page, Paige Green, Jennifer L. Guida

    Background: The purpose of this study was to describe the characteristics of the NIH‐funded grant portfolio focused on cancer and accelerated aging. Methods: Research project grants focused on cancer survivors and aging trajectories that were newly funded during fiscal years 2013 through 2023 were identified by first using a text mining algorithm from the NIH Research, Condition, and Disease Categorization (RCDC) system with cancer survivorship‐relevant terms and then a list of aging‐related terms that included aging, neurocognition, and physical function. Included grants were double coded to extract study characteristics. Results: A total of 166 grants were identified, with the National Cancer Institute (NCI) and National Institute on Aging (NIA) funding 62.0% and 23.5% of the grants, respectively. The number of newly funded grants rose from nine in 2013 to 27 in 2023. Overall, the majority were observational studies (65.1%); 45% included study samples of multiple cancer types. The most commonly examined outcomes were cognitive (54.4%) or physical (37.5%) functioning; 30% of grants incorporated an aging‐related biomarker. Few grants focused on racial and ethnic minority (3.0%) or rural cancer survivors (2.4%). Conclusions: This portfolio analysis showed an increase in the number of NIH‐funded grants focused on cancer survivors and accelerated aging, but notable gaps are evident. Given the rapidly growing survivor population, many of whom will experience accelerated aging trajectories, there is a critical need to better understand accelerated aging phenotypes and mechanisms, so that those at the highest risk for adverse aging‐related effects can be identified and interventions developed.


  • Response to: “Enhancing Geriatric Assessment in Cancer Rehabilitation: Suggestions for Future Research”

    by Supriya Mohile, Rachelle Brick, Marielle Jensen‐Battaglia, Brennan P. Streck, Lindsey Page, Eva Culakova

    See the related letter to the editor by Su and Zeng . in this issue.

  • Exploring geriatric assessment‐driven rehabilitation referral patterns and its influence on functional outcomes and survival in older adults with advanced cancer

    by Rachelle Brick, Marielle Jensen‐Battaglia, Brennan P. Streck, Lindsey Page, Rachael Tylock, Jenna Cacciatore, Karen Mustian, Jamil Khatri, Jeff Giguere, Elie G. Dib, et al.

    Background: Older adults with advanced cancer experience functional disability that warrants rehabilitation services; however, evidence indicates inconsistencies in referral. The purpose was to (1) identify predictors of geriatric assessment (GA)‐driven referrals to rehabilitation services and (2) explore associations between referral and change in function, health‐related quality of life (HRQoL), and overall survival among older adults with advanced cancer. Methods: This was a secondary analysis (NCT020107443, UG1CA189961) of a nationwide GA clinical trial. Patients were older adults with advanced cancer who had at least one GA‐defined physical performance or functional status impairment. Primary outcomes were oncologist‐initiated discussion about or referral to rehabilitation services after the GA (Aim 1) and decline in activities of daily living (ADL), Instrumental ADL (IADL), and HRQoL within 3 months, and overall survival at 1 year (Exploratory Aims). Analyses included multivariable logistic regression and Cox proportional hazards models. Demographic and clinical factors were controlled for by using 1:1 propensity score matching. Results: In total 265 patients were analyzed. After adjustment, impaired cognition (odds ratio [OR] = 2.25, p = 0.01), Karnofsky score indicating disability (OR = 2.86, p < 0.01), and receipt of monoclonal antibodies (OR = 1.95, p = 0.04) were associated with higher odds of referral. In contrast, polypharmacy was associated with lower odds of referral (OR = 0.31, p < 0.01). Referred patients were less likely to decline in ADL (OR 0.30, p = 0.07) and IADL (OR 0.64, p = 0.35), but more likely to decline in HRQoL (OR 1.20, p = 0.67) and have worse survival (HR 1.18, p = 0.62). Conclusions: Cancer treatment, polypharmacy, cognition, and disability status likely influence oncologists' decision to refer for rehabilitation. Referral was not independently associated with change in functional disability, HRQoL, or survival. Future studies should evaluate patients' utilization of rehabilitation services post‐referral and determine whether dose/timing of rehabilitation services influence clinical outcomes.


  • Associations Between Rehabilitation Utilization and Out-of-Pocket Costs Among Older Adults With Breast Cancer in the United States

    by Rachelle Brick, Courtney P. Williams, Luqin Deng, Michelle A. Mollica, Nicole Stout, Jessica Gorzelitz


  • Open Access

    National Cancer Institute-funded grants focused on synchronous telehealth cancer care delivery: a portfolio analysis

    by Roxanne E Jensen, Rachelle Brick, Joshua Medel, Priyanga Tuovinen, Paul B Jacobsen, Rebecca Hardesty, Robin C Vanderpool

    Background: Telehealth use increased during the COVID-19 pandemic and remains a complementary source of cancer care delivery. Understanding research funding trends in cancer-related telehealth can highlight developments in this area of science and identify future opportunities. Methods: Applications funded by the US National Cancer Institute (NCI) between fiscal years 2016 and 2022 and focused on synchronous patient-provider telehealth were analyzed for grant characteristics (eg, funding mechanism), cancer focus (eg, cancer type), and study features (eg, type of telehealth service). Of 106 grants identified initially, 60 were retained for coding after applying exclusion criteria. Results: Almost three-quarters (73%) of telehealth grants were funded during fiscal years 2020-2022. Approximately 67% were funded through R01 or R37 mechanism and implemented as randomized controlled trials (63%). Overall, telehealth grants commonly focused on treatment (30%) and survivorship (43%); breast cancer (12%), hematologic malignancies (10%), and multiple cancer sites (27%); and health disparity populations (ie, minorities, rural residents) (73%). Both audio and video telehealth were common (65%), as well as accompanying mHealth apps (20%). Telehealth services centered on psychosocial care, self-management, and supportive care (88%); interventions were commonly delivered by mental health professionals (30%). Conclusion: NCI has observed an increase in funded synchronous patient-provider telehealth grants. Trends indicate an evolution of awards that have expanded across the cancer control continuum, applied rigorous study designs, incorporated additional digital technologies, and focused on populations recognized for disparate cancer outcomes. As telehealth is integrated into routine cancer care delivery, additional research evidence will be needed to inform clinical practice.